biology-dictionary/;+scheduling.html

Breaking Biology Technology:Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 2 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3 Vivakor Confirms Record Date of Stock Dividend 2 Vivakor Confirms Record Date of Stock Dividend 3

[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A [0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research [0] Vivakor Confirms Record Date of Stock Dividend

Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5 Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2 Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3 Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 1 Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 2 LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 1 LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 2

[0] Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting [0] Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease [0] Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million